We use cookies to make your visit to our website as pleasant as possible. If you continue to use the website, you agree to our privacy policy and to the use of cookies. More information about cookies and how ImpediMed uses them is available here.
Accept Cookies
CLINICAL PRACTICE GUIDELINES
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship
Learn More

Breast Cancer-Related Lymphedema

Prevent Chronic Breast Cancer-Related Lymphedema with Early Detection and Intervention.

GET THE WHITEPAPER
Why Expanding Access to a Lymphedema Prevention Program is Needed for Cancer Patients

91% of patients believe cancer care teams should offer patients a Lymphedema Prevention Program.

Learn More

Enhance Survivorship and Maximize Patient Health

Understanding fluid shifts that occur in the body can help in the early detection, management, and monitoring of chronic diseases. Lymphedema, most frequently caused by cancer or cancer treatments such as surgery, radiation, and chemotherapy, is one of the most feared consequences of cancer treatment among breast cancer survivors. If left untreated, it can become a lifelong condition.

Enhance Survivorship and Maximize Patient Health with ImpediMed's SOZO Digital Health Platform

 

Enhance Survivorship and Maximize Patient Health

Proactive Care

Obtaining a baseline L-Dex® score upon breast cancer diagnosis is important for detecting breast cancer related-lymphedema and enhancing survivorship.

Precision Data

Utilizing the SOZO® Digital Health Platform in your clinical practice can greatly improve the quality of life for breast cancer patients and survivors1.

Dr. Pat Whitworth and Dr. Laura Lawson from the Nashville Breast Center explain why lymphedema prevention is a key component of a cancer survivorship program, and share their experience how implementing a lymphedema protocol, utilizing SOZO with L-Dex, has greatly improved the treatment and outlook for their patients.

Lymphedema Prevention Program

ImpediMed’s Lymphedema Prevention Program (LPP) uses SOZO with L-Dex to help detect lymphedema in breast cancer patients at the early stage, so that it can be treated and stopped from progressing to a lifelong condition.

Offer your patients peace of mind.

  • 1 in 5 breast cancer patients will develop lymphedema2
  • In the largest randomized trial to assess lymphedema prevention in breast cancer patients, 92% of patients with early detection using L-Dex and intervention did not progress to chronic lymphedema1
  • Learn more about ImpediMed’s Lymphedema Prevention Program for early detection and intervention of breast cancer-related lymphedema utilizing L-Dex and the Test, Trigger, Treat® protocol.

The L-Dex score, only available from ImpediMed, is designed to detect lymphedema-related fluid changes in the limbs.

Learn More About L-Dex

The L-Dex score, only available from ImpediMed, is designed to detect lymphedema-related fluid changes in the limbs.

Learn More About LPP

SOZO® Digital Health Platform

With the SOZO Digital Health Platform and L-Dex, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphedema.

Discover SOZO

SOZO® Digital Health Platform with nurse and patient

Clinical Evidence

NCCN Guidelines® recommend patient education and regular monitoring for the early detection of lymphedema.

Learn More

THE PREVENT TRIAL
STOPPING LYMPHEDEMA STARTS WITH PREVENT

Final 3-Year Primary Endpoint Results Published

SEE THE RESULTS
CLINICAL PRACTICE GUIDELINES
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship

The NCCN Guidelines® are consistent about the importance of early detection of lymphedema and use of an objective tool, such as bioimpedance spectroscopy.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 24, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Learn More

Additional guidelines support early detection and intervention

ASBrS

References

  1. Ridner SH, et al. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphatic Research and Biology 2022.
  2. NIH, National Cancer Institute: https://cancercontrol.cancer.gov/ocs/statistics/statistics.html accessed April 30, 2019.
  3. Shaitelman SF, et al. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin 2015;65:55-81.
  4. Caan, BJ et al. The Importance of Body Composition in Explaining the Overweight Paradox in Cancer. Cancer Res. 2018 April 15; 78(8): 1906 – 1912. doi:10.1158/0008-5472.CAN-17- 3287
  5. Artese AL et al. Assessment of Arm Lean Mass, Fat Mass, and Bone MineralDensity in Breast Cancer Survivors Without Lymphedema. Oncol Nurs Forum. 2021 Mar 1;48(2):166-172. doi: 10.1188/21.ONF.166-172. Affected arm = side with breast cancer; Unaffected arm = side without breast cancer
  6. Ward, L. Is BIS ready for prime time as the gold standard measure. Jrn Lymphoedema 2009;4(2)